These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17149134)

  • 21. Inotropic therapy for heart failure.
    Stevenson LW
    N Engl J Med; 1998 Dec; 339(25):1848-50. PubMed ID: 9854124
    [No Abstract]   [Full Text] [Related]  

  • 22. Should three-drug therapy be standard for heart failure?
    Harv Heart Lett; 1999 Jan; 9(5):5-6. PubMed ID: 9916561
    [No Abstract]   [Full Text] [Related]  

  • 23. Heart failure: an overview of consensus guidelines and nursing implications.
    Svendsen A
    Can J Cardiovasc Nurs; 2003; 13(2):30-4. PubMed ID: 12802836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Multidisciplinary guideline 'Heart failure 2010'].
    Voors AA; Walma EP; Twickler TB; Rutten FH; Hoes AW;
    Ned Tijdschr Geneeskd; 2011; 155():A2957. PubMed ID: 21447221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update in the approach to and management of heart failure.
    Gelow JM; Fang JC
    South Med J; 2006 Dec; 99(12):1346-55; quiz 1356-7, 1384. PubMed ID: 17233191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Better treatment of heart failure by measurements of natriuretic peptides. There are still remaining problems when it comes to the interpretation of measurement levels].
    Lindstedt G; Dahlström U; Fernlund P; Schaufelberger M; Stridsberg M
    Lakartidningen; 2001 Oct; 98(41):4444-8, 4450-2. PubMed ID: 11699251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From digoxin to angiotensin-converting enzyme inhibitors: issues in pharmacotherapy for congestive heart failure.
    Hackenbruck HA
    Clin Excell Nurse Pract; 2000 Jul; 4(4):197-204. PubMed ID: 11261079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
    Pfisterer M; Buser P; Rickli H; Gutmann M; Erne P; Rickenbacher P; Vuillomenet A; Jeker U; Dubach P; Beer H; Yoon SI; Suter T; Osterhues HH; Schieber MM; Hilti P; Schindler R; Brunner-La Rocca HP;
    JAMA; 2009 Jan; 301(4):383-92. PubMed ID: 19176440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and novel pharmacologic approaches in advanced heart failure.
    O'Connor CM; Gattis WA; Swedberg K
    Am Heart J; 1998 Jun; 135(6 Pt 2 Su):S249-63. PubMed ID: 9630089
    [No Abstract]   [Full Text] [Related]  

  • 30. Advanced heart failure: a call to action.
    Russell SD; Miller LW; Pagani FD
    Congest Heart Fail; 2008; 14(6):316-21. PubMed ID: 19076855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-type natriuretic peptide: from bench to bedside.
    Adams KF; Mathur VS; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S34-46. PubMed ID: 12594450
    [No Abstract]   [Full Text] [Related]  

  • 32. [Brain natriuretic Peptide. Diagnostic and prognostic value in chronic heart failure].
    Krüger S; Hoffmann R; Graf J; Janssens U; Hanrath P
    Med Klin (Munich); 2003 Oct; 98(10):562-7. PubMed ID: 14586510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Warning on diuretic use.
    Grundtvig M; Westheim A; Hole T; Flønaes B; Gullestad L;
    J Am Coll Cardiol; 2010 Jun; 55(23):2609-10; author reply 2610. PubMed ID: 20513605
    [No Abstract]   [Full Text] [Related]  

  • 34. Spironolactone in heart failure--a revived role for an old drug.
    Bradley C
    Intensive Crit Care Nurs; 2000 Dec; 16(6):403-4. PubMed ID: 11091472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.
    Harrison A; Morrison LK; Krishnaswamy P; Kazanegra R; Clopton P; Dao Q; Hlavin P; Maisel AS
    Ann Emerg Med; 2002 Feb; 39(2):131-8. PubMed ID: 11823766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
    Shinohara H; Fukuda N; Soeki T; Sakabe K; Onose Y; Tamura Y
    Heart Vessels; 2002 Dec; 17(2):47-52. PubMed ID: 12541093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy optimization of heart failure through the evaluation of the plasma concentration variation of B-type natriuretic peptide].
    Coppola A; De Paola G; Suppa M; Maggi B; Giancaspro G; Colzi M; Scarpellini MG; Lacenere L; Gerratana G; Aguglia F
    Clin Ter; 2006; 157(6):495-505. PubMed ID: 17228848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Assessment of Relaxin and B-Type Natriuretic Peptide Improves Diagnostic Value in Patients With Congestive Heart Failure.
    Han L; Luo J; Bai S; Jia Y; Chen X; Zhao Y; Chen L; Zhu X; Li Y; Jiang Y; Li X; Yang M; Li D; Teng X; Qi Y
    Am J Med Sci; 2017 Nov; 354(5):480-485. PubMed ID: 29173360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure.
    Watz R; Ekstrand AB; Engelbrektson V; Beermann B
    Eur J Clin Pharmacol; 2005 May; 61(3):209-14. PubMed ID: 15761755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical management of heart failure secondary to coronary artery disease.
    Challapalli S; Bonow RO; Gheorghiade M
    Coron Artery Dis; 1998; 9(10):659-74. PubMed ID: 9894618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.